Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02640664
Other study ID # CRFB002H2301E1
Secondary ID 2014-004048-36
Status Completed
Phase Phase 3
First received
Last updated
Start date June 16, 2016
Est. completion date April 21, 2022

Study information

Verified date January 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)


Description:

This was a multicenter, open-label extension study where the Visual Acuity (VA) assessment at the child's 5th birthday visit was performed. The study had 2 distinct periods (Epochs). Treatment with study ranibizumab (either as retreatment after ranibizumab had already been injected in the same eye or as switch ranibizumab treatment from study laser therapy administered in the core study) was permitted for eligible eyes with recurrence/worsening of ROP up to and including Week 40 from the baseline visit in the core study (Epoch 1). The remainder of the extension study up to the 5th birthday visit (Epoch 2) was observational, with no study treatment planned to be administered. In the core study, patients were randomized to 1 of the 3 treatment arms (ranibizumab 0.2 mg, ranibizumab 0.1 mg, and laser). Treatment arm assignment and patient identifier in the extension study remained the same as in the core study.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date April 21, 2022
Est. primary completion date April 21, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Months to 5 Years
Eligibility Inclusion Criteria: - Signed informed consent from parent(s) or legal guardian(s), in compliance with local requirements - The patient successfully completed the core study H2301, as defined by providing assessments at the Visit 112 (the last scheduled visit in the core study) or, if appropriate, at the last of the additional assessment visits as per protocol in H2301, whichever was latest - The patient received study treatment in both eyes at baseline of study H2301 Exclusion Criteria: - Patient had a medical condition or personal circumstance which precluded study participation or compliance with study procedures, as assessed by the Investigator - Patient had been discontinued from the core study H2301 at any time

Study Design


Intervention

Drug:
Ranibizumab
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

Locations

Country Name City State
Austria Novartis Investigative Site Graz
Austria Novartis Investigative Site Vienna
Belgium Novartis Investigative Site Brugge
Belgium Novartis Investigative Site Gent
Croatia Novartis Investigative Site Zagreb
Czechia Novartis Investigative Site Ostrava Poruba
Czechia Novartis Investigative Site Praha
Czechia Novartis Investigative Site Praha 4 - Podoli Czech Republic
Denmark Novartis Investigative Site Koebenhavn Ø
Egypt Novartis Investigative Site Alexandria
Estonia Novartis Investigative Site Tallinn
France Novartis Investigative Site Amiens
France Novartis Investigative Site Marseille
Germany Novartis Investigative Site Hannover
Greece Novartis Investigative Site Ampelokipi GR
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Thessaloniki GR
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Debrecen
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Madurai Tamil Nadu
India Novartis Investigative Site Mumbai Maharashtra
India Novartis Investigative Site New Delhi
India Novartis Investigative Site Vanchiyoor Thiruvanantapuram
Italy Novartis Investigative Site Firenze FI
Italy Novartis Investigative Site Fiumicino RM
Italy Novartis Investigative Site Perugia PG
Italy Novartis Investigative Site Roma RM
Japan Novartis Investigative Site Fuchu-city Tokyo
Japan Novartis Investigative Site Fukuoka city Fukuoka
Japan Novartis Investigative Site Fukuoka city Fukuoka
Japan Novartis Investigative Site Izumi-city Osaka
Japan Novartis Investigative Site Kurume city Fukuoka
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Ohtsu-city Shiga
Japan Novartis Investigative Site Ota-ku Tokyo
Japan Novartis Investigative Site Sapporo-city Hokkaido
Japan Novartis Investigative Site Setagaya-ku Tokyo
Japan Novartis Investigative Site Shimajiri-Gun Okinawa
Japan Novartis Investigative Site Sumida-ku Tokyo
Japan Novartis Investigative Site Toshima-ku Tokyo
Japan Novartis Investigative Site Yachiyo-city Chiba
Japan Novartis Investigative Site Zentsuji-city Kagawa
Lithuania Novartis Investigative Site Kaunas LTU
Malaysia Novartis Investigative Site Kota Kinabalu Sabah
Malaysia Novartis Investigative Site Kuala Lumpur Wilayah Persekutuan
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Timisoara
Russian Federation Novartis Investigative Site Cheboksary
Russian Federation Novartis Investigative Site Kazan
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Saint-Petersburg
Saudi Arabia Novartis Investigative Site Riyadh
Slovakia Novartis Investigative Site Bratislava
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taoyuan
Turkey Novartis Investigative Site Istanbul Bakirkoy
Turkey Novartis Investigative Site Meselik Eskisehir
Turkey Novartis Investigative Site Soguksu / Antalya
United Kingdom Novartis Investigative Site Manchester
United Kingdom Novartis Investigative Site Portsmouth
United States Novartis Investigative Site Ann Arbor Michigan
United States Novartis Investigative Site Aurora Colorado
United States Novartis Investigative Site Austin Texas
United States Novartis Investigative Site Baltimore Maryland
United States Novartis Investigative Site Chicago Illinois
United States Novartis Investigative Site Louisville Kentucky
United States Novartis Investigative Site Morgantown West Virginia
United States Novartis Investigative Site Rochester New York
United States Novartis Investigative Site Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Croatia,  Czechia,  Denmark,  Egypt,  Estonia,  France,  Germany,  Greece,  Hungary,  India,  Italy,  Japan,  Lithuania,  Malaysia,  Romania,  Russian Federation,  Saudi Arabia,  Slovakia,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The better-seeing eye was defined as the eye with the higher ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the right eye was assigned as the better-seeing eye. at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Secondary Number of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term Number of participants with ocular AEs starting during the core study and ongoing at extension baseline, or starting on/after extension baseline were reported. throughout the study, approximately 5 years
Secondary Number of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term Number of participants with non-ocular adverse events regardless of study treatment or procedure relationship (greater than or equal to 3% in any arm) by preferred term were reported. throughout the study, approximately 5 years
Secondary Visual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The worse-seeing eye was the eye with a lower ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the left eye was assigned as the worse-seeing eye. at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Secondary Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 40 Weeks Post Core Baseline Visit The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease. at 40 weeks post core baseline visit
Secondary Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease. at 52 weeks post core baseline visit
Secondary Number of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula at or before 40 weeks post baseline visit
Secondary Number of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)
Secondary Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis at or before 40 weeks post baseline visit
Secondary Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)
Secondary Number of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)
Secondary Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)
Secondary Number of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence. up to 40 weeks post baseline visit in the core study
Secondary Number of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence. Beyond Week 40, participants did not receive any study intervention and no new data was collected after 40 weeks post core baseline visit. up to 52 weeks post baseline visit in the core study
Secondary Number of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period Number of ranibizumab injections received in the treatment of participants with ROP up to and including 40 weeks post baseline visit in the core study were reported. up to and including 40 weeks post baseline visit in the core study
Secondary Refraction Status: Summary of Participants at Participant's 2 Years Corrected Age Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years corrected age at participant's 2 years corrected age (maximum 2 years and 4 months post core baseline visit)
Secondary Refraction Status: Summary of Participants at the Participant's Fifth Birthday Visit Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years' corrected age at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Secondary Change From Baseline in Weight Subject´s weight was reported to evaluate the physical development. Baseline of the core study, at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit) and at the subjects' fifth birthday (maximum 5 years and 4 months post core baseline visit)
Secondary Change From Baseline in Head Circumference Subject´s head circumference was reported to evaluate the physical development. Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Secondary Change From Baseline in Sitting Diastolic Blood Pressure Subject´s Sitting Diastolic Blood Pressure was reported to evaluate the physical development. Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Secondary Change From Baseline in Sitting Systolic Blood Pressure Subject´s Sitting Systolic Blood Pressure was reported to evaluate the physical development. Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Secondary Number of Participants With the Summary of Respiratory Function Status Number of participants with respiratory function status was reported at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Secondary Number of Participants With Hearing Impairment of Any Type Number of participants with hearing function status was reported at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Secondary Duration of Hospitalization Duration of hospitalization (from birth to first hospital discharge home) was reported to evaluate the health status of the subject From baseline of the core study up to 5 years and 4 months post core baseline visit
Secondary Weight at the Time of First Hospital Discharge Weight (gram) at the time of first hospital discharge was reported to evaluate the health status of the subject From baseline of the core study up to 5 years and 4 months post core baseline visit
See also
  Status Clinical Trial Phase
Terminated NCT04506619 - Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Completed NCT04004208 - Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy Phase 3
Recruiting NCT03253263 - A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants Phase 2
Completed NCT02386839 - Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP) Phase 2
Withdrawn NCT01470430 - VEGF In Systemic Circulation Of ROP-infants N/A
Completed NCT01054027 - Study on Effective Mydriasis in Premature Infants N/A
Active, not recruiting NCT04015180 - Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 Phase 3
Completed NCT01096784 - IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity Phase 2
Completed NCT02134457 - Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity Phase 2
Terminated NCT01954082 - Inositol to Reduce Retinopathy of Prematurity Phase 3